Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Maximilian, Jenzer"'
Autor:
Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul
Externí odkaz:
https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5
Autor:
Olaf Neumann, Anna-Lena Volckmar, Daniel Kazdal, Stefan Duensing, Michael Allgäuer, Jan Budczies, Peter Schirmacher, Martina Kirchner, Suranand Babu Talla, Fabian Stögbauer, Maximilian Jenzer, Eugen Rempel, Albrecht Stenzinger, Stefanie Zschäbitz, Constantin Schwab, Ildiko Kocsmar, Volker Endris
Publikováno v:
Genes, Chromosomes and Cancer. 59:406-416
Inflammatory gene signatures are currently being explored as predictive biomarkers for immune checkpoint blockade, and particularly for the treatment of renal cell cancers. From a diagnostic point of view, the nCounter analysis platform and targeted
Autor:
Thomas, Walle, Sunanjay, Bajaj, Joscha A, Kraske, Thomas, Rösner, Christiane S, Cussigh, Katharina A, Kälber, Lisa Jasmin, Müller, Sophia Boyoung, Strobel, Jana, Burghaus, Stefan M, Kallenberger, Christoph K, Stein-Thöringer, Maximilian, Jenzer, Antonia, Schubert, Steffen, Kahle, Anja, Williams, Birgit, Hoyler, Lin, Zielske, Renate, Skatula, Stefanie, Sawall, Mathias F, Leber, Russell Z, Kunes, Johannes, Krisam, Carlo, Fremd, Andreas, Schneeweiss, Jürgen, Krauss, Leonidas, Apostolidis, Anne Katrin, Berger, Georg M, Haag, Stefanie, Zschäbitz, Niels, Halama, Christoph, Springfeld, Romy, Kirsten, Jessica C, Hassel, Dirk, Jäger
Publikováno v:
Nature cancer. 3(9)
Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination u
Autor:
Eva Bonetti, Maximilian Jenzer, Cathleen Nientiedt, Adam Kaczorowski, Christine Geisler, Stefanie Zschäbitz, Dirk Jäger, Markus Hohenfellner, Stefan Duensing, Philipp Reimold
Publikováno v:
Urologia internationalis. 106(11)
Introduction: Cytokine-based immunotherapy (IT) has been the mainstay of systemic treatment of advanced renal cell carcinoma (RCC) from the late 1980s until 2007. With the introduction of immune checkpoint inhibitors, a renaissance of immune oncologi
Autor:
Philippa Lantwin, Frederik L. Giesel, Nassim Tawanaie Pour Sedehi, Dogu Teber, Anette Duensing, Magdalena Görtz, Elena Czink, Markus Hohenfellner, Rebecca Kreuter, Carine Pecqueux, Jonas Leichsenring, Peter Schirmacher, Martina Kirchner, Tobias Simpfendörfer, Anna-Lena Volckmar, Desiree Franke, Svenja Dieffenbacher, Joanne Nyarangi-Dix, Jürgen Debus, Jan-Philipp Radtke, Maximilian Jenzer, Volker Endris, Holger Sültmann, Leonidas Apostolidis, Shirin Hoveida, Cathleen Nientiedt, Clemens Kratochwil, Claudia Gasch, Katrin Kaltenecker, Viktoria Schütz, Stefan Duensing, Georgia Christofi, Olaf Neumann, Gencay Hatiboglu, Uwe Haberkorn, Carsten Grüllich, Stefan A. Koerber, Josef Mansour, Dirk Jäger, Georgi Tosev, Gita Schönberg, Albrecht Stenzinger, Luisa Hofer, Stefanie Zschäbitz, Sanjay Isaac
Publikováno v:
Urologic oncology. 38(7)
Background Defects in DNA damage repair genes characterize a subset of men with prostate cancer and provide an attractive opportunity for precision oncology approaches. The prevalence of such perturbations in newly diagnosed, treatment-naive patients
Autor:
Romy Kirsten, Matthias Scheffler, Elena Busch, Stefanie Zschäbitz, Barbara Wolf, Carsten Grüllich, Maximilian Jenzer, Rebecca Kramer, Christel Herold-Mende, Dirk Jäger, Andreas Mock
Publikováno v:
Cancer immunology, immunotherapy : CII. 68(12)
Checkpoint inhibitors (CPI) have significantly changed the therapeutic landscape of oncology. We adopted a non-invasive metabolomic approach to understand immunotherapy response and failure in 28 urological cancer patients. In total, 134 metabolites
Autor:
Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Benedikt Brors, Albrecht Stenzinger, Dirk Jäger, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Ursula Ehmer, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Felix J Hüttner, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Ulrich-Frank Pape, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Sebastian Schölch, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Christoph Springfeld, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz
Publikováno v:
ESMO Open
ESMO Open, Vol 4, Iss 6 (2019)
ESMO Open, Vol 4, Iss 6 (2019)
Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul
Autor:
Volker Endris, Cathleen Nientiedt, Fabian Stögbauer, Carsten Grüllich, Dirk Jäger, Adam Kaczorowski, Markus Hohenfellner, Stefanie Zschäbitz, Holger Sültmann, Maximilian Jenzer, Brian Kudlow, Skyler Mishkin, Anna-Lena Volckmar, Peter Keß, Anette Duensing, Maximilian Kippenberger, Stefan Duensing, Josh Haimes, Peter Schirmacher, Albrecht Stenzinger, Jonas Leichsenring
Publikováno v:
Cancer Immunology, Immunotherapy
Defects in DNA damage repair caused by mutations in BRCA1/2, ATM or other genes have been shown to play an important role in the development and progression of prostate cancer. The influence of such mutations on anti-tumor immunity in prostate cancer
Autor:
Christof Bernemann, Xin Chen, Cathleen Nientiedt, Jürgen Debus, Carsten Stephan, Anette Duensing, Martina Heller, Andres Jan Schrader, Michael Falkenstein, Holger Sültmann, Maximilian Jenzer, Sven Perner, Glen Kristiansen, Esther Herpel, Yuri Tolkach, Markus Hohenfellner, Carsten Grüllich, Dirk Jäger, Marcus V. Cronauer, Stefan Duensing
Publikováno v:
Urologic oncology. 36(4)
Background Overexpression of the androgen receptor (AR) splice variant 7 (AR-V7) has recently been reported to be associated with resistance to antihormonal therapy. Herein, we address the question whether tumor cells with AR-V7 expression can be det
Autor:
Werner Hohenberger, Sven Wach, Nathalie Britzen-Laurent, Andrea Liebl, Ludger Klein-Hitpass, Michael Stürzl, Tilman T. Rau, Ute Schaal, Arif B. Ekici, Roland S. Croner, Maximilian Jenzer, Vera Schellerer, Susanne Merkel, Elisabeth Naschberger, Bastian Keck, Sandra Grenz
Publikováno v:
Journal of Clinical Oncology. 32:e22012-e22012
e22012 Background: Tumor endothelial cells (TECs) were considered to be genetically stable and despite being different from normal endothelial cells (NECs) to exhibit a relatively homogeneous pheno...